Accueil   Diary - News   All news Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate

Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate

Phase 1 interim results showed an excellent immunogenicity profile after a single-shot vaccination and an acceptable safety profile, supporting further development.


 100% seroconversion rate achieved at Day 28 after a single-shot vaccination in a pooled analysis1 of all dose groups


 Pooled analysis showed a high antibody response based on geometric mean titre


 No serious adverse events or adverse events of special interest were reported up to Day 28

 

Saint Herblain (France), January 7, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet medical needs, today announced positive Phase 1 interim results for its Chikungunya vaccine candidate, VLA1553. The primary objective of VLA1553-101 Phase 1 study was to assess the overall safety and immunogenicity profile 28 days after a single vaccination across three dose levels.

 

Read the press release